SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    EI-Serag HB, Mason A. Rising incidence of hepatocellular carcinoma in United States. N Engl J Med. 1999; 340: 745750.
  • 2
    Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C. Gastroenterology. 1997; 112: 463472.
  • 3
    Shinagawa T, Ohto M, Kimura K, et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography: a study in 51 patients. Gastroenterology. 1984; 86: 495502.
  • 4
    Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR. 1995; 164: 885890.
  • 5
    Subramanyam BR, Balthazar EJ, Hilton S, Lefleur RS, Horii SC, Raghavendra BN. Hepatocellular carcinoma with venous invasion. Sonographic angiographic correlation. Radiology. 1984; 150: 793796.
  • 6
    Mathieu D, Grenier P, Lardé D, Vasile N. Portal vein involvement in hepatocellular carcinoma: dynamic CT features. Radiology. 1984; 152: 127132.
  • 7
    Okuda K, Musha H, Yamazaki T, et al. Angiographic demonstration of intrahepatic arterio-portal anastomoses in hepatocellular carcinoma. Radiology. 1977; 122: 5358.
  • 8
    Okuda K, Musha H, Yoshida T, et al. Demonstration of growing casts of hepatocellular carcinoma in the portal vein by celiac angiography: the thread and streaks sign. Radiology. 1975; 117: 303309.
  • 9
    Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K. Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer. 1983; 51: 863877.
  • 10
    Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver transplantation versus resection for hepatocellular carcinoma in cirrhosis. Ann Surg. 1993; 218: 145251.
  • 11
    The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990; 211: 277287.
  • 12
    Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993; 105: 488494.
  • 13
    Sato M, Watanabe Y, Ueda S, et al. Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology. 1996; 110: 15071514.
  • 14
    Livraghi T, Goldberg SN, Meloni F, Solbiati L, Gazelle GS. Hepatocellular carcinoma: comparison of efficacy between percutaneous ethanol instillation and radiofrequency. Radiology. 1999; 210: 655661.
  • 15
    Shiina S, Tagawa K, Unuma T, Terano A. Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. AJR. 1990; 154: 947951.
  • 16
    Livraghi T, Grigioni W, Mazziotti A, Sangalli G, Vettori C. Percutaneous ethanol injection of portal thrombosis in hepatocellular carcinoma: a new possible treatment. Tumori. 1990; 76: 394397.
  • 17
    Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989; 170: 783786.
  • 18
    Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment — study of 850 patients. Cancer. 1985; 56: 918928.
  • 19
    Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol. 1993; 23: 105109.
  • 20
    Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999; 29: 6267.
  • 21
    Calcly B. Natural history of primary and secondary tumors of the liver. Semin Oncol. 1983; 10: 127134
  • 22
    Bruix J. Treatment of hepatocellular carcinoma. Hepatology. 1997; 25: 259262.
  • 23
    Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997; 8: 117136.
  • 24
    Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000; 31: 5458.
  • 25
    Patt YZ, Charnsangavei C, Yoffe B, et al. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effect of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol. 1994; 12: 12041211.
  • 26
    Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin, and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology. 1998; 55: 3947.
  • 27
    Toyoda H, Nakano S, Kumada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology. 1995; 52: 295299.
  • 28
    Carr BI, Zajko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol. 1997; 24( suppl 6): S6-97S6-99.
  • 29
    Chung YH, Song H, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer. 2000; 88: 19861991.
  • 30
    Ando E, Yamashita F, Tanaka M, Tanigawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer. 1997; 79: 18901896.
  • 31
    Ando E, Masatoshi T, Yamashita F, et al. Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus. J Clin Gastroenterol. 2000; 31: 247249.
  • 32
    Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer. 2001; 91: 561569.
  • 33
    The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer, 2nd. Tokyo: Kanehara Shuppan, 1987: 18 (In Japanese).
  • 34
    Hermanek P, Sobin LH. TMN classification of malignant tumors, 4th edition. Berlin: Springer Verlag, 1987: 5961.
  • 35
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 36
    Tang ZY, Uy YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients. World J Surg. 1995; 19: 784789.
  • 37
    Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol. 2000; 7: 490495.
  • 38
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 39
    Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG. The liver and portal hypertention. Philadelphia, WB Saunders, 1964: 4951.
  • 40
    Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972; 34: 184200.
  • 41
    Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology. 1992; 16: 112117.
  • 42
    Breedis C, Young C. The blood supply of neoplasms in the liver. Am J Pathol. 1954; 10: 176182.
  • 43
    Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983; 10: 176182.
  • 44
    Paquet KJ, Kalk JF, Cuan-Orozco F, Siemens F, Koussouris P, Mercado MA. Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced hepatocellular carcinoma. Eur J Surg Oncol. 1992; 18: 156161.
  • 45
    Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989; 97: 965971.
  • 46
    Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A. 1986; 83: 89238925.
  • 47
    Hidalgo OF, Gonzalez F, Gil A, Campbell W, Barrajon E, Lacave AJ. 120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol. 1989; 12: 397401.
  • 48
    Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989; 7: 14071417.